18/11/2026

EMVision Medical Devices Ltd
ACN 620 388 230
Suite 4.01, 65 Epping Rd
Sydney NSW 2113
02 8667 5337
contact@emvision.com.au

ASX Release

emu™ REGIONAL BENEFITS CRC-P PROGRESS PAYMENT RECEIVED

Key Highlights

- **Cooperative Research Centres Projects (CRC-P) progress payment of $306,750 has been received.**
- **CRC-P funded Regional Benefits Study designed to generate clinical benefits evidence for the regional and remote use case of the emu™ bedside scanner.**
- **The regional use case addresses a global access need, beginning with ~400 rural, regional and remote hospitals in Australia and over 1,300 US Critical Access Hospitals. Similar models of care and similar diagnostic challenges are found across rural communities worldwide.**

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to advise that a Cooperative Research Centres Projects (CRC-P) progress payment of $306,750 has been received. $1.85m of the $3.0m grant has now been received.

The emu™ Regional Benefits Study, funded under the CRC-P grant, continues to advance alongside study partners the Australian Stroke Alliance, Titan Pre-Hospital Innovation and South Australia's Rural Support Service. The team has visited preferred study sites across rural and remote South Australia, with strong engagement from local clinicians. EMVision has also prepared a structured evaluation framework that positions the study to deliver more than clinical data, building the foundation for a sustainable model of care that can bring emu™ into routine stroke care in rural hospitals. The framework assesses ease of use, improvements in stroke care, clinician acceptance, reliability and long term sustainability beyond the study. Ethics submission for the study is scheduled for CY Q1 2027 and study activation in CY H2 2027.

Access to stroke care remains markedly unequal across Australia, with patients in regional hospitals 76% less likely to receive treatment in a stroke unit than those in metropolitan hospitals (Australian Stroke Clinical Registry). Under the study, emu™ devices will be placed in regional hospitals without ready access to CT imaging. The objective is to show that EMVision's point-of-care emu™ scanner can speed up stroke diagnosis and support earlier triage, transfer or treatment decisions for patients who would otherwise face lengthy transfers. A successful study outcome would establish a model that can be replicated throughout regional Australia and in comparable settings overseas. Discussions at recent international stroke conferences have reinforced the diagnostic bottlenecks and gaps in stroke outcomes faced by rural and regional communities, including in the US. EMVision's emu™ scanner is designed to address this need.

Authorised for release by the Managing Director & Company Secretary of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neurodiagnostic devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

About Stroke

Stroke is a medical emergency that occurs when blood flow to part of the brain is interrupted, either by a blocked vessel (ischaemic stroke) or bleeding into the brain (hemorrhagic stroke). The resulting lack of oxygen and nutrients can rapidly damage brain tissue, leading to disability or death if not treated promptly. Different stroke types require different types of care. Early recognition and fast access to diagnosis and appropriate care are critical, as timely intervention can significantly improve outcomes.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.